abstract |
A nanoparticulate dry powder composition comprising aggregates of a poorly soluble nanoparticulate crystalline drug, where by "poorly soluble" it is meant that the drug has a solubility in at least one liquid dispersion medium of less than about 10 mg / ml, where the aggregates have a diameter of less than or equal to about 100m, and where the drug: (i) has a surface modifier adsorbed on the surface, and (ii) has an effective average particle size of less than about 1000 nm, meaning that at least 50% of the drug particles have a particle size of less than about 1000 nm. |